BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment-- BioXcel Therapeutics said Monday it plans to initiate an at-home phase 3 trial of BXCL501, a potential treatment for agitation linked to bipolar disorder or schizophrenia, based on the US Food...